Showing results (291-300 of 353) with videos related to
Sort By:
Pageof 36
Journal Der Deutschen Dermatologischen Gesellschaft = Journal of the German Society of Dermatology : JDDG|October 18, 2021
Inpatient care for skin diseases in Germany: multi-source analysis on the current and future health care needsMatthias Augustin, Gefion Girbig, Anne Kis, et al.The Journal of Sexual Medicine|June 22, 2010
Sexual desire and the female sexual function index (FSFI): a sexual desire cutpoint for clinical interpretation of the FSFI in women with and without hypoactive sexual desire disorderEric P Gerstenberger, Raymond C Rosen, Jessica V Brewer, et al.European Journal of Clinical Pharmacology|January 28, 2022
The effect of BI 409306 on heart rate in healthy volunteers: a randomised, double-blind, placebo-controlled, crossover studyFabian Müller, Michael Sand, Glen Wunderlich, et al.Journal of Immunology (Baltimore, Md. : 1950)|October 4, 2008
B cells from patients with Graves' disease aberrantly express the IGF-1 receptor: implications for disease pathogenesisRaymond S Douglas, Vibharavi Naik, Catherine J Hwang, et al.Journal of Cosmetic Dermatology|May 29, 2024
Ready-to-use abobotulinumtoxinA solution versus powder botulinumtoxinA for treatment of glabellar lines: Investigators' and subjects' experience in a Phase IV studyPriyanka Chadha, Peter Arne Gerber, Said Hilton, et al.Journal of Breath Research|March 2, 2026
A Versatile Ex-Vivo Model Platform for Detection of Exhaled Drugs using Isolated Perfused Porcine LungsStefan Radermacher, Sascha Kreuer, Felix Maurer, et al.European Neuropsychopharmacology : the Journal of the European College of Neuropsychopharmacology|March 24, 2018
The safety, tolerability and pharmacokinetics of BI 409306, a novel and potent PDE9 inhibitor: Overview of three Phase I randomised trials in healthy volunteersViktoria Moschetti, Maria Kim, Michael Sand, et al.Pigment Cell & Melanoma Research|April 5, 2011
The stepwise two-photon excited melanin fluorescence is a unique diagnostic tool for the detection of malignant transformation in melanocytesDieter Leupold, Matthias Scholz, Goran Stankovic, et al.Journal of the American Academy of Dermatology|November 17, 2025
Bimekizumab demonstrated a favorable safety profile and high levels of efficacy with up to 2 years of treatment in patients with moderate to severe hidradenitis suppurativa: Pooled results from two phase 3 randomized, controlled trials and their open-label extensionChristopher J Sayed, Brian Kirby, Amit Garg, et al.The British Journal of Dermatology|November 29, 2024
Long-term efficacy and safety of secukinumab in patients with moderate-to-severe hidradenitis suppurativa: week 104 results from the SUNSHINE and SUNRISE extension trialAlexa B Kimball, Falk G Bechara, Aysha Badat, et al.Pageof 36